Last reviewed · How we verify

NCT04832022: COVID-RIC3

Longitudinal Follow-up of Patients With Chronic Inflammatory Rheumatisms (CIRs) Vaccinated Against COVID-19 Compared to Patients Refusing Vaccination

Completed Last updated 14 August 2023
What this trial tests

trial testing Biological samples in Rheumatic Diseases in 397 participants. Completed in 27 June 2023.

Timeline
7 April 2021
Primary endpoint
21 June 2022
27 June 2023

Quick facts

Lead sponsorUniversity Hospital, Montpellier
StatusCompleted
Study typeOBSERVATIONAL
Enrollment397
Start date7 April 2021
Primary completion21 June 2022
Estimated completion27 June 2023
Sites13 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Montpellier

Who can join

18 and older, any sex, with Rheumatic Diseases or SARS-CoV Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To date, studies on SARS-CoV2and vaccines have been mostly from the general population not exposed to immunosuppressants. The efficacy and safety of COVID-19 vaccines need to be evaluated in these populations.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Biological samples

Trials testing the same drug.

Other recruiting trials for Rheumatic Diseases

Currently open trials in the same condition.

Other University Hospital, Montpellier trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04832022.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing